---
company: Lumexa Imaging Holdings, Inc.
ticker: LMRI
form: 8-K
filed: 2026-08-12
accession: 0001193125-26-346813
source: https://www.sec.gov/Archives/edgar/data/2071288/000119312526346813/
---

# Lumexa Imaging Holdings (LMRI) earnings release, August 12, 2026

Lumexa Imaging Holdings, Inc. (LMRI) · Form 8-K, Item 2.02 · Filed 2026-08-12 · [SEC filing](https://www.sec.gov/Archives/edgar/data/2071288/000119312526346813/)

Lumexa Imaging Announces Second Quarter 2026 Results

RALEIGH, N. C., August 12, 2026—Lumexa Imaging (Nasdaq: LMRI), one of the nation’s largest providers of outpatient imaging services, today reported results for the second quarter ended June 30, 2026, and updated its full year 2026 outlook.

“During the second quarter, we continued to build on our momentum, delivering strong same-center growth, expanding our mix of advanced imaging and ramping new centers,” said Caitlin Zulla, Chief Executive Officer of Lumexa Imaging. “Some highlights include announcing four new imaging centers year to date and a joint venture with Hospital for Special Surgery (HSS), a globally recognized leader in musculoskeletal health, marking our ninth health system partnership and our second new joint venture in the past twelve months.”

“With a large and growing addressable market and durable demand tailwinds, we believe Lumexa Imaging is well positioned to deliver sustained, profitable growth while expanding access to high-quality, lower-cost imaging for patients, providers, and payors.”

Second

Quarter 2026 Highlights:

All comparisons are to the quarter ended June 30, 2025, unless otherwise noted

2026 Full Year Outlook:

Lumexa Imaging provided an update on its guidance for the full year ended December 31, 2026.

Lumexa Imaging Earnings Conference Call and Webcast

Lumexa Imaging will host a conference call to discuss its second quarter 2026 results, as well as its 2026 outlook, on August 12, 2026 at 5:00 p.m. ET.

The call can be accessed via live audio webcast online at ir.lumexaimaging.com. A replay of the webcast will be available at the same link shortly after the completion of the call and will remain available for approximately one year.

Statement Regarding Use of

Non-GAAP

Financial Measures

This press release uses Adjusted EBITDA and Adjusted EPS, financial measures that are not calculated in accordance with GAAP. We use Adjusted EBITDA and

Adjusted EPS, in conjunction with GAAP financial measures, as an integral part of managing our business and to, among other things: (i) monitor and evaluate the performance of our business operations and financial performance;

(ii) facilitate internal comparisons of the historical operating performance of our business operations; (iii) review and assess the operating performance of our management team; and (iv) analyze and evaluate financial and strategic planning decisions regarding future operations and annual operating budgets. For a reconciliation of Adjusted EBITDA and Adjusted EPS to the most directly comparable measure calculated in accordance with GAAP, please see below.

We have not reconciled our Adjusted EBITDA or Adjusted EPS guidance to their most directly comparable GAAP measures because we do not and are not able to provide guidance for those GAAP measures due to the uncertainty and potential variability of certain reconciling items, including transaction costs, severance and executive recruiting. Because such items cannot be provided without unreasonable efforts, we are unable to provide the corresponding reconciliations. However, such reconciling items could have a significant impact on our future results.

About Lumexa Imaging

Lumexa Imaging is a nationwide provider of outpatient medical imaging. With over 5,000 team members and greater than 190 outpatient imaging centers, our team conducted approximately 4 million outpatient procedures system-wide in 2025. We are a partner of choice for health systems and radiologists, delivering best-in-class clinical excellence, operations, and state-of-the-art technology across our platform.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release may be forward-looking statements. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,”

“contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,”

“should,” “target,” or “will,” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. Forward-looking statements in this release include, but are not limited to, statements regarding our expectations regarding our financial position and operating performance, including our guidance for full year 2026 and our assumptions underlying such guidance; our ability to drive future growth and execute on our goals and strategies; and our expectations regarding our product innovation. Our expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including but not limited to those risk factors identified in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of our Annual Report on Form

10-K for the year ended December 31, 2025 and our later dated Quarterly Reports on Form

10-Q, each as filed with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligations to update any forward-looking statements, except as required by law.

Investor Contact

Sue Dooley

Lumexa Imaging

Sue.Dooley@LumexaImaging.com

Media Contact

Melissa Weston

Lumexa Imaging elissa.Weston@LumexaImaging.com

Lumexa Imaging Q2 2026 Outpatient Volumes Highlights:

LUMEXA IMAGING HOLDINGS, INC. AND SUBSIDIARIES

## Financial statements

### Income Statement (Three Months Ended June 30, — (Unaudited) (in thousands))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 |
|---|---:|---:|
| REVENUES: | Net patient service revenue | 203,735 | 198,185 |
| REVENUES: | Management fee and other revenue | 60,427 | 53,217 |
| REVENUES: | Total revenues | 264,162 | 251,402 |
| OPERATING EXPENSES: | Cost of operations, excluding depreciation and amortization | 225,285 | 212,265 |
| OPERATING EXPENSES: | General and administrative expenses | 24,397 | 18,689 |
| OPERATING EXPENSES: | Depreciation and amortization | 10,083 | 9,279 |
| OPERATING EXPENSES: | (Gain) loss on disposal of property and equipment | -24 | 16 |
| OPERATING EXPENSES: | Total operating expenses | 259,741 | 240,249 |
| OPERATING EXPENSES: | Equity in earnings of unconsolidated affiliates | 18,619 | 16,527 |
| OPERATING EXPENSES: | INCOME FROM OPERATIONS | 23,040 | 27,680 |
| OTHER EXPENSES: | Interest expense | 16,222 | 30,097 |
| OTHER EXPENSES: | Loss on extinguishment and modification of debt | 1,053 |  |
| OTHER EXPENSES: | Total other expenses | 17,275 | 30,097 |
| OTHER EXPENSES: | INCOME (LOSS) BEFORE INCOME TAXES | 5,765 | -2,417 |
| OTHER EXPENSES: | Income tax provision | 3,020 | 4,809 |
| OTHER EXPENSES: | NET INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) | 2,745 | -7,226 |
| Weighted average shares outstanding: | Basic | 95,983,246 | 69,526,574 |
| Weighted average shares outstanding: | Diluted | 96,039,426 | 69,526,574 |
| Net income (loss) per common share | Basic | 0.03 | -0.1 |
| Net income (loss) per common share | Diluted | 0.03 | -0.1 |

### Income Statement (Six Months Ended June 30, — (Unaudited) (in thousands))

| | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|
| REVENUES: | Net patient service revenue | 401,053 | 390,483 |
| REVENUES: | Management fee and other revenue | 115,646 | 105,920 |
| REVENUES: | Total revenues | 516,699 | 496,403 |
| OPERATING EXPENSES: | Cost of operations, excluding depreciation and amortization | 443,040 | 420,662 |
| OPERATING EXPENSES: | General and administrative expenses | 44,732 | 36,181 |
| OPERATING EXPENSES: | Depreciation and amortization | 20,005 | 18,330 |
| OPERATING EXPENSES: | (Gain) loss on disposal of property and equipment | 113 | -146 |
| OPERATING EXPENSES: | Total operating expenses | 507,890 | 475,027 |
| OPERATING EXPENSES: | Equity in earnings of unconsolidated affiliates | 33,643 | 31,845 |
| OPERATING EXPENSES: | INCOME FROM OPERATIONS | 42,452 | 53,221 |
| OTHER EXPENSES: | Interest expense | 32,553 | 59,946 |
| OTHER EXPENSES: | Loss on extinguishment and modification of debt | 1,053 |  |
| OTHER EXPENSES: | Total other expenses | 33,606 | 59,946 |
| OTHER EXPENSES: | INCOME (LOSS) BEFORE INCOME TAXES | 8,846 | -6,725 |
| OTHER EXPENSES: | Income tax provision | 4,384 | 8,188 |
| OTHER EXPENSES: | NET INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) | 4,462 | -14,913 |
| Weighted average shares outstanding: | Basic | 95,983,240 | 69,524,980 |
| Weighted average shares outstanding: | Diluted | 96,011,335 | 69,524,980 |
| Net income (loss) per common share | Basic | 0.05 | -0.21 |
| Net income (loss) per common share | Diluted | 0.05 | -0.21 |

### Income Statement (Three Months Ended June 30, — (Unaudited) (in thousands))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 |
|---|---:|---:|
| Net income (loss) | 2,745 | -7,226 |
| Depreciation and amortization | 10,083 | 9,279 |
| Income tax provision | 3,020 | 4,809 |
| Amortization of basis difference | 573 | 500 |
| Interest expense | 16,222 | 30,097 |
| Stock-based compensation | 12,737 | 8,346 |
| Loss on extinguishment and modification of debt | 1,053 |  |
| Loss (gain) on disposal of property and equipment | -24 | 16 |
| Severance and executive recruiting(1) | 686 | 803 |
| Strategic initiatives and implementation(2) | 2,659 | 1,018 |
| Transaction costs(3) | 707 | 3,875 |
| Litigation and settlements(4) | 1,173 |  |
| Other(5) | 87 | 142 |
| Adjustments for equity in earnings of unconsolidated affiliates(6) | 4,724 | 4,615 |
| Adjusted EBITDA | 56,445 | 56,274 |

### Income Statement (Six Months Ended June 30, — (Unaudited) (in thousands))

| | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|
| Net income (loss) | 4,462 | -14,913 |
| Depreciation and amortization | 20,005 | 18,330 |
| Income tax provision | 4,384 | 8,188 |
| Amortization of basis difference | 1,105 | 1,000 |
| Interest expense | 32,553 | 59,946 |
| Stock-based compensation | 25,011 | 14,720 |
| Loss on extinguishment and modification of debt | 1,053 |  |
| Loss (gain) on disposal of property and equipment | 113 | -146 |
| Severance and executive recruiting(1) | 1,631 | 2,173 |
| Strategic initiatives and implementation(2) | 3,484 | 1,886 |
| Transaction costs(3) | 3,289 | 7,464 |
| Litigation and settlements(4) | 1,202 | -128 |
| Other(5) | 82 | 158 |
| Adjustments for equity in earnings of unconsolidated affiliates(6) | 9,270 | 8,596 |
| Adjusted EBITDA | 107,644 | 107,274 |

### Income Statement (Three Months Ended June 30, — (Unaudited) (in thousands))

| | Three Months Ended June 30, – 2026 | Six Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Components of “management fee and other revenues:” | Fees for managing joint ventured outpatient sites and other third party services | 26,103 |  | 20,578 |  |
| Components of “management fee and other revenues:” | Zero margin pass-throughs of employee, IT and other site level costs paid by Lumexa | 34,324 |  | 32,639 |  |
| Components of “management fee and other revenues:” | Total revenues | 60,427 |  | 53,217 |  |
| Components of “management fee and other revenues:” | Fees for managing joint ventured outpatient sites and other third party services |  | 47,601 |  | 40,654 |
| Components of “management fee and other revenues:” | Zero margin pass-throughs of employee, IT and other site level costs paid by Lumexa |  | 68,045 |  | 65,266 |
| Components of “management fee and other revenues:” | Total revenues |  | 115,646 |  | 105,920 |

### Balance Sheet (June 30, 2026 — (Unaudited) (in thousands))

| | June 30, 2026 | December 31, 2025 |
|---|---:|---:|
| ASSETS | Cash and cash equivalents | 69,705 | 58,828 |
| ASSETS | Accounts receivable | 120,637 | 112,942 |
| ASSETS | Accounts receivable, related party | 20,024 | 18,893 |
| ASSETS | Other receivables | 31,552 | 19,015 |
| ASSETS | Prepaid expenses | 14,498 | 17,582 |
| ASSETS | Total current assets | 256,416 | 227,260 |
| ASSETS | Property and equipment, net of accumulated depreciation | 156,062 | 144,709 |
| ASSETS | Operating lease right-of-use assets | 77,033 | 76,555 |
| ASSETS | Investments in unconsolidated affiliates | 423,331 | 423,191 |
| ASSETS | Intangible assets, net of accumulated amortization | 39,722 | 41,335 |
| ASSETS | Goodwill | 807,554 | 807,554 |
| ASSETS | Other assets | 48,654 | 43,953 |
| ASSETS | TOTAL ASSETS | 1,808,772 | 1,764,557 |
| LIABILITIES AND EQUITY | Accounts payable | 27,062 | 44,857 |
| LIABILITIES AND EQUITY | Accrued expenses and other current liabilities | 109,167 | 95,561 |
| LIABILITIES AND EQUITY | Accounts receivable pledging arrangement | 1,267 | 1,599 |
| LIABILITIES AND EQUITY | Current portion of long-term debt | 14,330 | 13,112 |
| LIABILITIES AND EQUITY | Current portion of finance lease liabilities | 14,597 | 11,552 |
| LIABILITIES AND EQUITY | Current portion of operating lease liabilities | 11,932 | 12,513 |
| LIABILITIES AND EQUITY | Total current liabilities | 178,355 | 179,194 |
| LIABILITIES AND EQUITY | Long-term debt, less current maturities | 819,753 | 819,029 |
| LIABILITIES AND EQUITY | Long-term finance lease liabilities, less current maturities | 41,177 | 33,262 |
| LIABILITIES AND EQUITY | Long-term operating lease liabilities, less current maturities | 72,296 | 71,437 |
| LIABILITIES AND EQUITY | Deferred income taxes | 43,592 | 40,772 |
| LIABILITIES AND EQUITY | Other liabilities | 38,538 | 34,740 |
| LIABILITIES AND EQUITY | Total liabilities | 1,193,711 | 1,178,434 |
| EQUITY: | Common stock, $0.001 par value, 1,000,000,000 shares authorized, 96,074,976 shares issued and outstanding at June 30, 2026 and 96,109,927 shares issued and outstanding at December 31, 2025 | 96 | 96 |
| EQUITY: | Additional paid-in-capital | 1,241,563 | 1,217,087 |
| EQUITY: | Accumulated deficit | -626,598 | -631,060 |
| EQUITY: | Total equity | 615,061 | 586,123 |
| EQUITY: | TOTAL LIABILITIES AND EQUITY | 1,808,772 | 1,764,557 |

### Cash Flow (Six Months Ended June 30, — (Unaudited) (in thousands))

| | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|
| CASH FLOWS FROM OPERATING ACTIVITIES: | Net income (loss) | 4,462 | -14,913 |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities | Depreciation and amortization | 20,005 | 18,330 |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities | Amortization of operating lease right-of-use assets | 7,956 | 7,424 |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities | Amortization of debt issuance costs | 1,437 | 2,871 |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities | Amortization of cloud computing implementation costs | 760 | 184 |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities | Write-off of debt issuance costs related to extinguishment of debt | 46 |  |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities | Equity in earnings of unconsolidated affiliates | -33,643 | -31,845 |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities | Distributions from investments in unconsolidated affiliates | 36,869 | 32,820 |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities | Loss on disposal of property and equipment | 113 | -146 |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities | Deferred income taxes | 2,820 | 1,477 |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities | Stock-based compensation | 25,011 | 14,720 |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities | Other | -535 |  |
| Changes in operating assets and liabilities: | Accounts receivable | -7,695 | -6,870 |
| Changes in operating assets and liabilities: | Accounts receivable, related party | -1,131 | -2,035 |
| Changes in operating assets and liabilities: | Capitalized cloud computing implementation costs | -1,647 | -1,421 |
| Changes in operating assets and liabilities: | Other receivables | -12,537 | -5,410 |
| Changes in operating assets and liabilities: | Prepaid expenses | 3,034 | -7,028 |
| Changes in operating assets and liabilities: | Other assets | -4,723 | -11,311 |
| Changes in operating assets and liabilities: | Accounts payable | -18,596 | 1,214 |
| Changes in operating assets and liabilities: | Accrued expenses and other current liabilities | 18,085 | -11,002 |
| Changes in operating assets and liabilities: | Other liabilities | 3,798 | 7,018 |
| Changes in operating assets and liabilities: | Operating lease liabilities | -8,156 | -5,966 |
| Changes in operating assets and liabilities: | Net cash provided by (used in) operating activities | 35,733 | -11,889 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | Proceeds from sale or disposal of property and equipment | 40 | 713 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | Acquisition of intangible asset | -600 |  |
| CASH FLOWS FROM INVESTING ACTIVITIES: | Purchases of property and equipment | -14,985 | -5,602 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | Contributions to investments in unconsolidated affiliates | -3,366 |  |
| CASH FLOWS FROM INVESTING ACTIVITIES: | Net cash used in investing activities | -18,911 | -4,889 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | Payment of third-party debt issuance costs | -154 |  |
| CASH FLOWS FROM FINANCING ACTIVITIES: | Proceeds from long-term debt | 9,536 | 496 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | Payments of long-term debt | -8,393 | -7,821 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | Proceeds from revolving line of credit |  | 5,000 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | Payments of finance lease liabilities | -6,602 | -2,998 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | Capital contributions |  | 715 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | Repayments on accounts receivable pledging arrangement | -332 |  |
| CASH FLOWS FROM FINANCING ACTIVITIES: | Net cash used in financing activities | -5,945 | -4,608 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | 10,877 | -21,386 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | CASH AND CASH EQUIVALENTS, beginning of period | 58,828 | 26,131 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | CASH AND CASH EQUIVALENTS, end of period | 69,705 | 4,745 |
